This announcement is a separate document:
信立泰：关于恩那度司他新适应症获得临床试验批准通知书的公告
Shenzhen Salubris Pharmaceuticals: Announcement on the approval of clinical trial notification for new indications of Enadastron.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated